Overcoming the Hurdles of Real-World Data Access through a Federated Global Network

Executive summary

This white paper explores how life sciences teams can overcome the barriers of Real-World Data (RWD) access to accelerate evidence generation and strengthen drug development. It outlines how global, analysis-ready harmonized datasets can expand study reach without regulatory complexity, deliver deeper insights at speed, and improve reimbursement effectiveness. It also highlights how RWD can serve as an External Control Arm (ECA) to support label expansion and showcases two real success stories from leading biopharma companies who used RWD to expand patient access and generate robust Real-World Evidence (RWE).

Download this white paper to learn about:

• Global RWD access enables broader study populations without navigating fragmented regulatory environments.
• Harmonized, analysis-ready datasets accelerate evidence generation, improve decision-making, and maximize data ROI.
• RWD-driven ECAs can support label expansion, reimbursement strategies, and real-world validation of therapeutic value.